EMA Authorised: Talzenna (talazoparib) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA authorised Talzenna (talazoparib) for breast cancer. The marketing authorization holder is Pfizer Europe MA EEIG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Talzenna (talazoparib)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Pfizer Europe MA EEIG. Decision date: 19/06/2025